These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 24756371)

  • 1. New strategies in ewing sarcoma: lost in translation?
    Arnaldez FI; Helman LJ
    Clin Cancer Res; 2014 Jun; 20(12):3050-6. PubMed ID: 24756371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway.
    van Maldegem AM; Bovée JV; Peterse EF; Hogendoorn PC; Gelderblom H
    Eur J Cancer; 2016 Jan; 53():171-80. PubMed ID: 26765686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma.
    Vormoor B; Curtin NJ
    Curr Opin Oncol; 2014 Jul; 26(4):428-33. PubMed ID: 24840521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospects and challenges for the development of new therapies for Ewing sarcoma.
    Grohar PJ; Helman LJ
    Pharmacol Ther; 2013 Feb; 137(2):216-24. PubMed ID: 23085431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigational therapies for Ewing sarcoma: a search without a clear finding.
    Vornicova O; Bar-Sela G
    Expert Opin Investig Drugs; 2016 Jun; 25(6):679-86. PubMed ID: 26988130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the tumor microenvironment of Ewing sarcoma.
    Morales E; Olson M; Iglesias F; Luetkens T; Atanackovic D
    Immunotherapy; 2021 Dec; 13(17):1439-1451. PubMed ID: 34670399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ewing's sarcoma: overcoming the therapeutic plateau.
    Subbiah V; Kurzrock R
    Discov Med; 2012 Jun; 13(73):405-15. PubMed ID: 22742646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ewing sarcoma: investigational mono- and combination therapies in clinical trials.
    Gartrell J; Rodriguez-Galindo C
    Expert Opin Investig Drugs; 2021 Jun; 30(6):653-663. PubMed ID: 33870845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting.
    Kailayangiri S; Altvater B; Meltzer J; Pscherer S; Luecke A; Dierkes C; Titze U; Leuchte K; Landmeier S; Hotfilder M; Dirksen U; Hardes J; Gosheger G; Juergens H; Rossig C
    Br J Cancer; 2012 Mar; 106(6):1123-33. PubMed ID: 22374462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging.
    Liebsch L; Kailayangiri S; Beck L; Altvater B; Koch R; Dierkes C; Hotfilder M; Nagelmann N; Faber C; Kooijman H; Ring J; Vieth V; Rossig C
    Br J Cancer; 2013 Aug; 109(3):658-66. PubMed ID: 23839490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
    Danieau G; Morice S; Rédini F; Verrecchia F; Royer BB
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing Natural Killer Cell Targeting of Pediatric Sarcoma.
    Omer N; Nicholls W; Ruegg B; Souza-Fonseca-Guimaraes F; Rossi GR
    Front Immunol; 2021; 12():791206. PubMed ID: 34804076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma.
    Englisch A; Altvater B; Kailayangiri S; Hartmann W; Rossig C
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28313. PubMed ID: 32729251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.
    Lamhamedi-Cherradi SE; Menegaz BA; Ramamoorthy V; Vishwamitra D; Wang Y; Maywald RL; Buford AS; Fokt I; Skora S; Wang J; Naing A; Lazar AJ; Rohren EM; Daw NC; Subbiah V; Benjamin RS; Ratan R; Priebe W; Mikos AG; Amin HM; Ludwig JA
    J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27576731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental therapies and clinical trials in bone sarcoma.
    Chugh R
    J Natl Compr Canc Netw; 2010 Jun; 8(6):715-25. PubMed ID: 20581301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review of phase-I/II trials enrolling refractory and recurrent Ewing sarcoma: Actual knowledge and future directions to optimize the research.
    Felix A; Berlanga P; Toulmonde M; Landman-Parker J; Dumont S; Vassal G; Le Deley MC; Gaspar N
    Cancer Med; 2021 Mar; 10(5):1589-1604. PubMed ID: 33452711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children's Oncology Group (COG) New Agents for Ewing Sarcoma Task Force.
    Bailey K; Cost C; Davis I; Glade-Bender J; Grohar P; Houghton P; Isakoff M; Stewart E; Laack N; Yustein J; Reed D; Janeway K; Gorlick R; Lessnick S; DuBois S; Hingorani P
    F1000Res; 2019; 8():. PubMed ID: 31031965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging therapies in Ewing sarcoma.
    Strauss SJ; Berlanga P; McCabe MG
    Curr Opin Oncol; 2024 Jul; 36(4):297-304. PubMed ID: 38775200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ewing Sarcoma, an Update on Molecular Pathology with Therapeutic Implications.
    de Alava E
    Surg Pathol Clin; 2017 Sep; 10(3):575-585. PubMed ID: 28797503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.